Fig. 3: In vitro CD47 and CRT regulations by LRT nanomedicine on the plasma membrane of LLC cells. | Nature Communications

Fig. 3: In vitro CD47 and CRT regulations by LRT nanomedicine on the plasma membrane of LLC cells.

From: Nanomedicine-based co-delivery of a calcium channel inhibitor and a small molecule targeting CD47 for lung cancer immunotherapy

Fig. 3

a Intracellular calcium flow analysis by flow cytometry of LLC cells after various treatments. N = 3 samples with similar results. b CLSM images of LLC cells after different treatments for 24 h. Fluo-4 (green) was used for cellular calcium observation and the nucleus were stained with Hoechst 33342 (blue). Scale bars, 50 μm. N = 3 samples with similar results. c Bio-TEM images of pristine LLC cells (control) and the LLC cells after the treatment with LRT nanomedicine for 16 h. Yellow arrows marks reveal the normal ER, while red ones indicate the ER under stress state. N = 3 samples with similar results. d Western blot analysis of ER stress-associated proteins of LLC cells after various treatments. The data were expressed as means ± SD (N  =  3 samples). e CLSM images showing the CRT translocation of LLC cells treated with PBS, LDH, LR, LT or LRT. Blue and red fluorescence show DAPI-stained nucleus and CRT exposure on the cell surface, respectively. Scale bar = 50 μm. Cells were not permeabilized prior to immunofluorescence staining. N = 3 samples with similar results. f Flow cytometric analyses for CD47 and CRT regulations of LLC cells after various treatments, representative of 3 independent experiments. Source data are provided as a Source Data file.

Back to article page